Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, leading to increased insulin synthesis and decreased glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, it is primarily excreted via the enterohepatic system.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Initial/Maintenance dose:** 5 mg orally once daily.
* **Maximum dose:** 5 mg once daily.
## Pediatric Dosing
Safety and effectiveness have not been established in patients <18 years of age.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Drug Interactions:** If used with strong CYP3A4 or P-glycoprotein inducers (e.g., rifampin), glycemic control should be monitored; consider an alternative agent if control is inadequate.
## Contraindications
* Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis (use with caution).
## Adverse Effects
* **Common:** Nasopharyngitis, upper respiratory tract infection, headache, arthralgia.
* **Serious:** Acute pancreatitis (seek medical attention if severe abdominal pain), bullous pemphigoid, severe joint pain, hypoglycemia (when used with insulin secretagogues or insulin).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations; monitor glycemic control.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; dose reduction of the secretagogue or insulin may be required.
## Monitoring
* **HbA1c:** Approximately every 3–6 months.
* **Renal Function:** Not required due to excretion profile, but standard for diabetes management.
* **Clinical:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **No renal adjustment needed:** This is a distinct advantage of linagliptin over other gliptins (e.g., sitagliptin, saxagliptin) in patients with chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Weight Neutral:** Generally weight-neutral.
* **Safety:** Does not require titration; generally well-tolerated with a low risk of hypoglycemia when used as monotherapy.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify drug doses, contraindications, and clinical protocols against the current FDA-approved prescribing information or institutional clinical guidelines before prescribing or administering medication.
